PE-Labeled GUCY2C Fc&Avi Tag: The "Triple-Function Sentinel" in Colorectal Cancer Diagnosis and Treatment

This protein is a "one-stop" platform reagent constructed through genetic engineering and enzymatic/chemical modifications, designed to maximize the application potential of GUCY2C targeting.

The core of the probe is the extracellular domain of the human guanylate cyclase C receptor. GUCY2C is a transmembrane receptor whose natural ligands are guanylin and uroguanylin. This module retains the biological activity of specifically binding to cell surface GUCY2C antigens, enabling precise recognition of colorectal cancer cells and normal intestinal epithelial cells (as internal controls) while showing almost no binding to other tissue cells.

The fused immunoglobulin Fc fragment (typically IgG1 Fc) provides two core functions:

Signal Amplification and Universal Detection Interface: Offers a universal binding site for any fluorescent, enzymatic, or metal-labeled anti-Fc secondary antibodies. This allows users to "freely allocate" detection signals to different channels or achieve exponential signal amplification based on experimental needs.

Functional Crosslinking and Endocytosis Studies: By adding anti-Fc antibodies, artificial crosslinking and clustering of GUCY2C receptors on the cell surface can be induced, mimicking the effects of ligands or multivalent antibodies, and used to study receptor downstream signaling activation, endocytosis kinetics, or as a positive control.

A 15-amino acid short peptide tag that can be efficiently and specifically biotinylated by biotin ligase.

Unlimited Customization Portal: After biotinylation, the probe can be irreversibly conjugated with any functional molecule (e.g., different fluorescent dyes, quantum dots, magnetic beads, drug toxins, or radioactive nuclides) pre-labeled with streptavidin/avidin through its high-affinity binding, enabling "plug-and-play" functional expansion.

The probe is pre-covalently labeled with R-phycoerythrin, a multimeric fluorescent protein composed of multiple chromophores.

Signal Intensity Assurance: PE is one of the brightest fluorophores available for flow cytometry, with signal intensity far exceeding small-molecule dyes (e.g., FITC, Alexa Fluor 647), providing extremely high signal-to-noise ratios for detecting low-abundance expression or rare cellular events (e.g., circulating tumor cells).

This probe is a "trinity" strategic platform. PE is the "main attack unit" for direct, powerful reconnaissance; the Fc tag is the "standardized tactical interface" connecting various support capabilities; and AviTag is the "frontline call device" that can summon specialized equipment (different functional warheads or modules) at any time. Together, they ensure comprehensive, customizable research capabilities for GUCY2C targets.

The power of this probe lies in its support for multiple operational modes, from simple detection to complex functional studies.

PE-Labeled Direct, Strong Signal Output: No secondary antibodies are needed; one-step fluorescence labeling of GUCY2C-expressing cells with ultra-high brightness is achieved. PE's intensity enables clear identification of target cells in complex backgrounds (e.g., whole blood, ascites, or tissue digests rich in debris), making it ideal for flow cytometry detection of circulating tumor cells.

Fluorescence Channel Liberation: When the PE channel is occupied by other critical markers in the experimental panel, an unlabeled PE version (or Fc tag masking of PE signals) can be used first, followed by detection with anti-Fc secondary antibodies conjugated to APC, BV421, or other dyes, thereby "transferring" GUCY2C signals to other available channels and perfectly resolving channel conflicts in multicolor experiments.

Cascade Signal Amplification: For samples with extremely low expression levels, a three-step method of "probe + biotinylated anti-Fc secondary antibody + streptavidin-PE/APC" can be employed to further amplify signals.

Induced Receptor Crosslinking: Utilizing its Fc fragment, GUCY2C receptor crosslinking and internalization can be artificially induced on live cells by adding anti-Fc antibodies, enabling studies of signal transduction, endocytic pathways, and effects on cellular biological behavior after receptor activation by antibodies or ligands.

Competition and Blockade Experiments: As a high-affinity soluble receptor, it can competitively block endogenous ligands or therapeutic antibodies from binding to cell surface GUCY2C, validating the receptor dependence of specific functions.

On-Demand Functional Customization: Through AviTag biotinylation, this probe can serve as a universal "warhead carrier," easily conjugated with streptavidin-coupled near-infrared fluorescent dyes, magnetic beads, or therapeutic payloads, rapidly generating customized probes for in vivo imaging, cell sorting, or targeted delivery studies.

This probe holds pivotal value in basic research, clinical diagnosis, and therapeutic development for colorectal cancer.

Specific "Bait" for Peripheral Blood CTC Detection: Leveraging PE's ultra-high brightness, GUCY2C-positive CTCs can be enriched and identified with high sensitivity and specificity from the peripheral blood of colorectal cancer patients. Its expression specificity effectively distinguishes CTCs from blood cells, with counts closely correlated to tumor stage, prognosis, and recurrence risk.

Postoperative MRD Monitoring: After radical surgery, dynamic monitoring of GUCY2C+ CTCs in patient blood serves as a potential liquid biopsy tool for predicting early recurrence and assessing adjuvant chemotherapy efficacy.

Specific Tissue Section Marker: Used for multiplex immunofluorescence staining of colorectal cancer tissue specimens, specifically labeling cancerous tissue (GUCY2C+) and adjacent normal intestinal epithelium (GUCY2C+, serving as internal references), while combining with other markers (e.g., Ki-67, CDX2, immune checkpoint molecules) to analyze tumor heterogeneity, proliferative activity, and immune microenvironment.

Lymph Node and Distant Metastasis Identification: In suspected metastatic lymph nodes or biopsy tissues from the liver, lungs, etc., GUCY2C staining helps confirm the colorectal cancer origin of metastases, aiding differential diagnosis.

Target Screening and Validation: Before patient enrollment, using this probe to precisely quantify tumor cell surface GUCY2C expression levels and uniformity is a critical companion diagnostic step to determine eligibility for GUCY2C-targeted therapies.

Therapeutic Kinetics Monitoring: During treatment, dynamic monitoring of changes in GUCY2C antigen density and positivity in patient CTCs or biopsy tissues assesses therapeutic pressure on target cell clearance and provides early warning of immune escape due to antigen loss or downregulation.

Preclinical Pharmacodynamic Evaluation: In animal models, leveraging the probe's detection capabilities evaluates CAR-T cell tumor homing, ADC drug targeting enrichment, and killing effects on GUCY2C+ cells.

Studying GUCY2C's Biological Functions: Utilizing its crosslinking function, explore GUCY2C signaling's role in maintaining intestinal epithelial homeostasis, regulating cell proliferation and apoptosis, and its abnormal activation mechanisms during carcinogenesis.

Exploring Metastasis Mechanisms: By detecting GUCY2C expression differences in cell lines with varying metastatic potential or patient-derived CTCs, study this molecule's role in the "seed" properties of colorectal cancer metastasis.

As a platform tool, its future development will deeply integrate into cutting-edge precision medicine fields.

Single-Cell Multi-Omics Analysis: Combining single-cell sorting and sequencing technologies, isolate individual GUCY2C+ CTCs from peripheral blood for whole-genome, transcriptome, or methylome sequencing, enabling non-invasive tumor molecular evolution monitoring.

Exosomal Surface Protein Analysis: Conjugate biotinylated probes with streptavidin magnetic beads to develop methods for capturing and detecting GUCY2C-positive tumor-derived exosomes in blood, serving as an effective complement to CTC detection.

Using AviTag to conjugate the probe with near-infrared fluorescent dyes, develop versions for intraoperative fluorescence imaging. In colorectal cancer surgery, real-time visualization of tumor margins and detection of suspicious lymph node micrometastases guide more precise tumor resection.

Develop "theranostic" probes: The same AviTag-biotinylated core module can be conjugated with diagnostic fluorescent dyes and therapeutic radioactive nuclides separately. Preoperative imaging localization is performed first, followed by intraoperative navigation or targeted radiotherapy, achieving a closed loop of diagnosis and treatment.

Combining high-content imaging systems, use this probe in 3D tumor organoid models for high-throughput screening of compounds that modulate GUCY2C expression or function.

Leveraging its detection capabilities, validate GUCY2C expression levels in blood or tissues as independent biomarkers for predicting chemotherapy or immunotherapy responses in large-scale cohorts.

PE-Labeled GUCY2C Fc&Avi Tag is a strategically valuable "trinity sentinel" in the field of precision medicine for colorectal cancer. Leveraging GUCY2C's exceptional tumor specificity, it integrates PE's reconnaissance brightness, Fc's tactical versatility, and AviTag's strategic expandability, constructing a powerful and highly flexible research and translation platform. From serving as a sensitive "catcher" of circulating tumor cells for non-invasive disease monitoring to acting as a tissue-specific "paintbrush" depicting tumor microecology; from providing precise "target maps" for revolutionary cell therapies to equipping future intraoperative navigation with "molecular searchlights," this multifunctional probe is playing an increasingly critical role across the entire colorectal cancer diagnosis and treatment chain. In the future, with rapid advancements in liquid biopsy, molecular imaging, and cell therapy technologies, this programmable molecular platform will continue evolving into a powerful engine connecting basic discoveries and clinical innovations in colorectal cancer, delivering core momentum for improving patient outcomes.